Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Remington

Showing results (21-30 of 410) with videos related to

Pageof 41
Sort By:
Neuropharmacology|June 14, 2020
Antipsychotics Circa 2020: What are we thinking?Gary Remington, Shitij Kapur
Journal of Psychiatry & Neuroscience : JPN|June 26, 2020
Clozapine and COVID-19Gary Remington, Valerie Powell
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2012
Validation of an abbreviated quality of life scale for schizophreniaGagan Fervaha, Gary Remington
Psychological Assessment|July 3, 2013
Invalid responding in questionnaire-based research: implications for the study of schizotypyGagan Fervaha, Gary Remington
Clinical Schizophrenia & Related Psychoses|July 26, 2017
Valbenazine for Tardive DyskinesiaOliver Freudenreich, Gary Remington
Evidence-Based Mental Health|August 21, 2012
Review: maintenance antipsychotics prevent relapse in patients with schizophreniaOfer Agid, Gary Remington
Clinical Schizophrenia & Related Psychoses|July 11, 2012
Antipsychotic dosing: extended, and transientPhilip Seeman, Gary Remington
Schizophrenia Bulletin|July 24, 2010
Antipsychotic dosing: how much but also how often?Gary Remington, Shitij Kapur
Journal of Psychiatry & Neuroscience : JPN|December 24, 2013
Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effectsGary Remington, Margaret Hahn
Psychopharmacology|June 6, 2013
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorderHiroyoshi Takeuchi, Gary Remington
Pageof 41

Showing results (21-30 of 410) with videos related to

Sort By:
Pageof 41
Neuropharmacology|June 14, 2020
Antipsychotics Circa 2020: What are we thinking?Gary Remington, Shitij Kapur
Journal of Psychiatry & Neuroscience : JPN|June 26, 2020
Clozapine and COVID-19Gary Remington, Valerie Powell
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2012
Validation of an abbreviated quality of life scale for schizophreniaGagan Fervaha, Gary Remington
Psychological Assessment|July 3, 2013
Invalid responding in questionnaire-based research: implications for the study of schizotypyGagan Fervaha, Gary Remington
Clinical Schizophrenia & Related Psychoses|July 26, 2017
Valbenazine for Tardive DyskinesiaOliver Freudenreich, Gary Remington
Evidence-Based Mental Health|August 21, 2012
Review: maintenance antipsychotics prevent relapse in patients with schizophreniaOfer Agid, Gary Remington
Clinical Schizophrenia & Related Psychoses|July 11, 2012
Antipsychotic dosing: extended, and transientPhilip Seeman, Gary Remington
Schizophrenia Bulletin|July 24, 2010
Antipsychotic dosing: how much but also how often?Gary Remington, Shitij Kapur
Journal of Psychiatry & Neuroscience : JPN|December 24, 2013
Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effectsGary Remington, Margaret Hahn
Psychopharmacology|June 6, 2013
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorderHiroyoshi Takeuchi, Gary Remington
Pageof 41